跳至主要内容
临床试验/CTRI/2009/091/000863
CTRI/2009/091/000863已完成3 期

An open label, comparative, multicentric study to assess the efficacy and safety of fixed dose combination capsules of Telmisartan & Indapamide (as sustained release) in comparison with Telmisartan tablets in patients suffering from hypertension

Cadila Healthcare Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients of either sex more than or equal to 18 years of age (No upper age limit was mentioned in our Protocol for this clinical trial).
  • 2.Patients with hypertension (defined as supine systolic and/or diastolic blood pressure more than 140 mm Hg and 90 mm Hg respectively)
  • 3.Informed consent of the patient/relative

排除标准

  • 1.Pregnancy and/or Lactation
  • 2.Patients with anuria, progressive & severe oliguria, hepatic coma, hypokalaemia, hyponatremia, hypochloremia, volume depletion, hyperuricaemia, secondary hypertension, congestive heart failure, systemic lupus erythematosus.
  • 3.Patients with hepatic and /or renal dysfunction or bilateral renal artery stenosis.
  • 4.Patients with a history of known hypersensitivity to either Telmisartan or Indapamide or to other sulfonamide derivatives or to any other component of the study drugs
  • 5.Patients with any other serious concurrent illness or malignancy
  • 6.Patients with continuing history of alcohol and / or drug abuse
  • 7.Participation in another clinical trial in the past 3 months

研究者

相似试验